Needham maintains TransMedics Group at Buy, raises price target to $110 from $106
Needham reaffirmed its Buy rating for TransMedics Group and increased its price target to $110 from $106, suggesting a 59.5% upside from the Nov 5 close of $68.98.
How this was made

The 30-second read
Why it matters
The upgrade may attract short‑term interest and support the stock toward the new target.
Market read
Analyst target raise provides a modest bullish signal for TMED.
What to watch
No new product or regulatory news accompanies the target change.
Background
Needham maintains a Buy rating on TransMedics Group and lifts its price target by 3.8% to $110.
Market effects
May lift sentiment in the medical device sector for similar small‑cap innovators.
Limited to U.S. small‑cap investors.
Low
Counterpoint
Target raises for micro‑caps can be premature; price may already reflect optimism.
Key entities
- companyTransMedics Group
Medical device company listed on Nasdaq (TMED).
- analystNeedham
Equity research firm issuing the rating and target.



